Yukiko Shimoda

Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients.

Y. Ohe, N. Yamamoto, S. Murakami, 2022, Clinical lung cancer.

Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis.

Y. Ohe, N. Yamamoto, H. Horinouchi, 2022, Lung cancer.

Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients

Y. Yatabe, Y. Ohe, N. Yamamoto, 2021, Anticancer Research.

Substance P-evoked Cl(-) secretion in guinea pig distal colonic epithelia: interaction with PGE(2).

S. Karaki, A. Kuwahara, Y. Hosoda, 2002, American journal of physiology. Gastrointestinal and liver physiology.

Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations

Y. Ohe, N. Yamamoto, H. Horinouchi, 2023, Cancer Immunology, Immunotherapy.

Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non‐small cell lung cancer patients

Y. Ohe, N. Yamamoto, H. Horinouchi, 2023, Cancer medicine.

Differential Immune-Related Microenvironment Determines PD-1/PD-L1 Blockade Efficacy in Advanced Non-Small Cell Lung Cancer Patients.

T. Kohno, Y. Ohe, S. Matsumoto, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.